Description
XYMOGEN OmegaPure PRM 60 Softgels: Featuring Pro-Resolving Mediators
Pro-resolving mediators (PRMs) are metabolites derived from omega-3 and omega-6 fatty acids. The most abundant PRMs are 14-HDHA, 17-HDHA, and 18-HEPE. These PRMs are further metabolized into naturally occurring signaling molecules called specialized pro-resolving mediators (SPMs). The primary function of SPMs is to downregulate the inflammatory response following the initial immune reaction, facilitating a return to homeostasis. They are also known as “resolving agonists.” Specialized pro-resolving mediators (SPMs) specifically target immune cells to help turn off or resolve the inflammatory response that occurs during acute injury or illness. If this inflammation is not resolved, it can persist even after the initial phase has ended, increasing the risk of developing serious chronic health problems. This is the 60 softgel size.
What are the benefits of XYMOGEN OmegaPure PRM?
– Supplies EPA and DHA, which are precursors to pro-resolving lipid mediators.
– Promotes the activity of specialized pro-resolving lipid mediators.
– Provides building blocks that support the natural resolution of the immune response.
The positive benefits of omega-3 fatty acids for various clinical conditions are likely due to the action of specialized pro-resolving mediators (SPMs). The SPM family consists of four structurally distinct groups of signaling molecules: lipoxins; resolvins derived from eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA); as well as protectins and maresins, which are derived from DPA and DHA. Each SPM has a specific structure that is crucial for its biological function. The endogenous biochemical pathways for SPMs counteract the production of pro-inflammatory mediators, such as cytokines, chemokines, and inflammatory eicosanoids, thereby promoting a healthy inflammatory response.
Have PRMs and SPMs been proven to work in studies?
Both in vitro and animal studies have demonstrated the effect of SPMs on resolution. Results of a study that explored the contribution of unresolved inflammation to heart failure after myocardial infarction in rodents found that resolvins reduced pro-fibrotic genes and collagen deposition in cardiac tissue, leading to a reduced risk of heart failure. In other animal research, resolvin E1 was shown to exert action on experimental models of inflammatory conditions, such as periodontitis, colitis, and peritonitis, in brain reperfusion. Resolvin E1 was also identified in the resolution of allergic airway responses. D2, another resolvin phenotype, was recognized as a regulator of the inflammatory response in mice with microbial sepsis. Cell culture studies have also suggested that resolvin E1 decreases polymorphonuclear neutrophil infiltration and T-cell migration, reduces TNFα and IFN-γ secretion, inhibits chemokine formation, and blocks IL-1–induced NF-κB activation. Resolvin E1 also stimulates macrophage phagocytosis of apoptotic polymorphonuclear neutrophil and is a potent modulator of pro-inflammatory leukocyte expression adhesion molecules.
A randomized, double-blind crossover study in adult subjects (N = 21) assessed the response difference to EPA and DHA as precursors to SPMs. Subjects with chronic inflammation were first given 10-week supplementation with 3 g/d of EPA. After a 10-week washout period, the same subjects were supplemented with 3 g/d of DHA. The study results suggested that supplementation with EPA and DHA have distinct effects on ex vivo monocyte inflammatory response by differently regulating cytokine expression.
The effect of SPMs in limiting neutrophil infiltration into inflammatory sites, enhancing phagocytosis of apoptotic cells, and promoting tissue regeneration in cell cultures and animal models of inflammation is promising. However, further research is needed to better understand SPM biosynthesis and tissue- and stimulus-specific molecular signatures of the resolution, to define dosages, and to determine the application of these effects in human subjects.
XYMOGEN OmegaPure PRM contains an enhanced marine lipid concentrate of omega-3 fatty acid ethyl esters with a standardized level of PRMs. The concentrate is a result of a proprietary fractionation method used to enrich 18-HEPE, 17-HDHA, and 14-HDHA. Metabolites of PRMs are emerging as a promising modality for providing building blocks to support the natural resolution of the immune response.
What are XYMOGEN products?
Xymogen products are science-backed supplements designed to support your overall health and well-being. Discover how Xymogen products can help you achieve your health goals. Read more about XYMOGEN products.
How can I get started with XYMOGEN OmegaPure PRM?
Are you ready to get started feeling better? Getting started with the XYMOGEN OmegaPure PRM supplement is easy. Simply schedule an appointment with Cunningham Clinic to discuss your options and then pick up your nutraceutical grade XYMOGEN OmegaPure PRM!
